| Molecular Interaction Atlas (MIA) |
|
| Indication(s) of Mecamylamine |
| Disease Entry |
ICD 11 |
Status |
REF |
| Essential hypertension |
BA00
|
Approved |
[2] |
|
|
|
Mecamylamine Interacts with 1 DTT Molecule(s)
| DTT Name |
DTT ID |
UniProt ID |
Mode of Action |
REF |
|
Nicotinic acetylcholine receptor (nAChR)
|
TTJSZTB
|
NOUNIPROTAC
|
Antagonist
|
[5] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
|
|
Mecamylamine Interacts with 5 DOT Molecule(s)
| DOT Name |
DOT ID |
UniProt ID |
Mode of Action |
REF |
|
Receptor-type tyrosine-protein phosphatase alpha (PTPRA)
|
OTZA82J1
|
PTPRA_HUMAN
|
Decreases Expression
|
[4] |
|
Fasciculation and elongation protein zeta-1 (FEZ1)
|
OTWCXPRE
|
FEZ1_HUMAN
|
Decreases Expression
|
[4] |
|
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF)
|
OTT5JX1F
|
LITAF_HUMAN
|
Decreases Expression
|
[4] |
|
Stress-induced-phosphoprotein 1 (STIP1)
|
OT7TXLOX
|
STIP1_HUMAN
|
Decreases Expression
|
[6] |
|
Golgin subfamily A member 4 (GOLGA4)
|
OTCMEHNJ
|
GOGA4_HUMAN
|
Increases Expression
|
[6] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
|
| Indication(s) of Maprotiline |
| Disease Entry |
ICD 11 |
Status |
REF |
| Depression |
6A70-6A7Z
|
Approved |
[3] |
| Major depressive disorder |
6A70.3
|
Approved |
[2] |
| Mixed anxiety and depressive disorder |
N.A.
|
Investigative |
[3] |
|
|
|
Maprotiline Interacts with 1 DTT Molecule(s)
| DTT Name |
DTT ID |
UniProt ID |
Mode of Action |
REF |
|
Norepinephrine transporter (NET)
|
TTAWNKZ
|
SC6A2_HUMAN
|
Inhibitor
|
[7] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
|
|
Maprotiline Interacts with 2 DME Molecule(s)
| DME Name |
DME ID |
UniProt ID |
Mode of Action |
REF |
|
Cytochrome P450 1A2 (CYP1A2)
|
DEJGDUW
|
CP1A2_HUMAN
|
Metabolism
|
[8] |
|
Cytochrome P450 2D6 (CYP2D6)
|
DECB0K3
|
CP2D6_HUMAN
|
Metabolism
|
[8] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
|
|
|
|
|
|
|
|